Cosmetic use of an extract of lysimachia christinae

Abstract

The present invention relates to the non-therapeutic cosmetic use of an extract of Lysimachia christinae for improving and / or maintaining the biomechanical properties of the skin and / or mucous membranes. It further relates to a non-therapeutic cosmetic care method using the extract of Lysimachia christinae or a composition comprising it.

Description

Cosmetic use of an extract of Lysimachia christinae Technical Field

[0001] The present invention relates to the non-therapeutic cosmetic use of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or mucous membranes. In particular, the use according to the invention allows for the improvement and / or maintenance of the firmness, tone, density, thickness, and / or vitality of the skin and / or mucous membranes. The invention also allows for the improvement and / or maintenance of the radiance of the complexion of healthy skin and / or mucous membranes.

[0002] Furthermore, the present invention also relates to a cosmetic treatment method comprising the topical application to at least one area of ​​healthy skin and / or mucous membranes of an extract of Lysimachia christinae and / or a cosmetic composition containing it, in order to improve and / or maintain the biomechanical properties of healthy skin and / or mucous membranes. The method according to the invention is designed to improve and / or maintain the firmness, tone, density, and / or thickness of the dermis, and / or the vitality of healthy skin and / or mucous membranes. The invention further enables the improvement and / or maintenance of the radiance of the complexion of healthy skin and / or mucous membranes. Previous technique

[0003] The structure and properties of the skin change under the effect of complex biological, physical and biomechanical processes, resulting in a loss of firmness and tone as well as a decrease in the density and thickness of the dermis, particularly under the effect of a decrease in the collagen level of the extracellular matrix.

[0004] The extracellular matrix of the skin and mucous membranes is composed of four types of molecules: collagen and elastin fibers, glycoproteins, and highly hydrated polysaccharides that form a gel-like structure within the matrix. Collagen fibers play a predominant role in maintaining the structure and properties of the skin and mucous membranes. in particular their firmness, their tone, and gives the dermis its thickness and density.

[0005] Collagen is synthesized by fibroblasts. This protein, a constituent of the extracellular matrix (ECM), is present in large quantities in vertebrate tissues. It belongs to a large family comprising 29 different types. Among the various types of collagen, type I collagen is found in many human tissues such as tendons, ligaments, cornea, and skin, located more specifically in the dermis. Type I collagen is the predominant collagen in skin and mucous membranes. Fibrillar collagen is formed from procollagen fibers, which are then assembled into a network and stabilized by cross-linking. Collagen gives tissues their mechanical strength and, consequently, contributes to maintaining their firmness and tone.Under the influence of various intrinsic and / or extrinsic factors, the collagen level can decrease, leading to a loss of firmness and tone of the skin and / or mucous membranes as well as a decrease in the density and thickness of the dermis and therefore of the skin and / or mucous membranes.

[0006] Matrix metalloproteinases (MMPs) constitute a family of 23 proteases that degrade all components of the extracellular matrix. In particular, the degradation of collagen by matrix metalloproteinases, especially types I and III, leads to a loss of firmness and tone, as well as a decrease in the thickness and density of the dermis of the skin and / or mucous membranes. Therefore, modulating their expression actively contributes to tissue remodeling and changes in the biomechanical properties of the skin and / or mucous membranes.

[0007] On the other hand, the link between NAD+ and ATP production has also been proven, where the intracellular NAD+ / NADH ratio controls the rate of ATP synthesis by regulating the flow through NAD(H)-related dehydrogenases and by activating NAD+-dependent enzymes (Matthew A. Walker, Rong Tian, ​​NAD(H) in mitochondrial energy transduction: implications for health and disease. Curr. Opin. Physiol. 2018 June; 3:101-109).

[0008] Nicotinamide mononucleotide or NMN, a precursor of NAD+, reduces melanogenesis in aged melanocytes by regulating the signaling of receptors associated with melanogenesis; NAD+ has also shown its ability to reduce the same melanogenesis signaling pathway (Sofia Britoa, Jin-Myoung Baeka, Byungsun Chab, Hyojin Heoa, Su-Hyun Leec, Lei Leib, So Young Junga, So Min Leeb, Sang Hun Leeb, Byeong-Mun Kwakd, Sehyun Chaee, Mi-Gi Leef, Bum-Ho Bina. Nicotinamide mononucleotide reduces melanin production in aged melanocytes by inhibiting cAMP / Wnt signaling. Journal of Dermatological Science 106 (2022) 159-169).

[0009] Thus, by promoting cellular respiration and inhibiting certain melanogenesis signaling pathways, the NAD+ molecule helps to increase the radiance of the complexion.

[0010] There is therefore a constant need in the field of cosmetics for alternative natural active ingredients, capable of improving and / or maintaining the biomechanical properties of healthy skin and / or healthy mucous membranes, in particular their firmness, tone, thickness and density of their dermis, as well as their vitality.

[0011] The Plaintiff discovered in a particularly surprising and unexpected way that an extract of Lysimachia christinae, in particular of the aerial parts, and preferentially of the leaves, makes it possible to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes, in particular their firmness, tone, thickness and density of their dermis, as well as their vitality.

[0012] The plant Lysimachia christinae belongs to the genus Lysimachia and the family Primuiaceae. Native to China, it is a creeping, perennial, and fast-growing herbaceous plant that can reach 20 to 60 cm in height. It forms clumps by developing its network of roots and creeping stems. The leaves are green, oval to orbicular or even kidney-shaped, hairless and glossy, alternate with petioles 1 to 3 cm long. The stems are delicate, grayish-green or reddish-purple in color. The flowers are yellow, solitary, bell-shaped, with 5 lobes. The leaves are oval to lanceolate, with 5 stamens. The plant is hermaphroditic and is pollinated by insects. It flowers from May to June and bears fruit from July to October.

[0013] An extract of Lysimachia christinae has been described for its properties on keratinocytes, through its restorative and hydrating action on the epidermal barrier (Hyun et al., Evaluation of the Skin Barrier Strengthening and Moisturizing Ability of Lysimachia christinae Hance Extract, The Korean Society of Culture and Convergence, December 2020. Vol.42, No.12).

[0014] An anti-inflammatory composition comprising, as active ingredients, an extract of Lysimachia christinae cultivated using desalinated volcanic seawater, an extract of peony cultivated using desalinated volcanic seawater, or paeoniflorin was described in application KR 2022 0136525 A. This composition was described as useful for relieving skin problems and strengthening skin barrier function. However, only the Lysimachia christinae extract failed to induce a measurable effect on keratinocyte formation and thus on improving skin barrier function, unlike the other two extracts. Furthermore, this document does not specify the particular plant part to be used; the examples use the whole plant.

[0015] A method for preparing an extract of Giechoma iongituba Kupr. with a skin barrier function was described in application KR 2022 0094724 A. However, Giechoma iongituba Kupr. is a different plant from Lysimachia christinae, as can be seen in particular by the color of its flowers (Giechoma iongituba Kupr. has purple flowers, while Lysimachia christinae has yellow flowers). No example in this document specifically describes or suggests the species Lysimachia christinae.

[0016] On the other hand, to the Applicant's knowledge, no prior art discloses or suggests an extract of Lysimachia christinae for cosmetic use or a cosmetic treatment process to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes, much less to improve and / or maintain the firmness and / or tone of healthy skin and / or healthy mucous membranes and / or the density of the dermis and / or the thickness of the dermis and / or the vitality of healthy skin and / or healthy mucous membranes. Summary of the invention

[0017] A first object of the invention thus relates to the non-therapeutic cosmetic use of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0018] A second object of the invention relates to a non-therapeutic cosmetic care method comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae or a cosmetic composition comprising it, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes. Description of the implementation methods ^^Cosmetic use

[0020] A first object of the invention relates to the non-therapeutic cosmetic use, advantageously by topical route, of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0021] In particular, the non-therapeutic cosmetic use, advantageously by topical application, of an extract of Lysimachia christinae, is to maintain and / or improve the firmness and / or tone of healthy skin and / or healthy mucous membranes and / or the density of the dermis and / or the thickness of the dermis, of healthy skin and / or healthy mucous membranes, preferentially the firmness of healthy skin and / or healthy mucous membranes.

[0022] Advantageously, the use according to the invention, particularly by topical route, is therefore to increase and / or maintain the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers. Even more preferably, the use according to the invention, particularly by topical route, is to increase the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

[0023] Advantageously, the use according to the invention, particularly by topical route, is to increase and / or maintain the synthesis of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers. Even more preferably, the use according to the invention, particularly by topical route, is to increase the synthesis of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0024] Advantageously, the use according to the invention, particularly by topical application, is to inhibit the degradation of collagen, especially type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0025] Advantageously, the use according to the invention, particularly by topical application, is to inhibit the degradation of collagen, especially type I collagen, preferentially of collagen fibers, more preferably of type I collagen fibers, by decreasing the amount of matrix metalloproteinase(s) (MMP), particularly type I matrix metalloproteinase(s) (MMPI) and / or type III (MMP3).

[0026] Advantageously, the use according to the invention, particularly by topical application, is to inhibit the degradation of collagen, especially type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers, by inhibiting the synthesis and / or secretion of matrix metalloproteinase(s) (MMP), particularly type I matrix metalloproteinase(s) (MMPI) and / or type III (MMP3).

[0027] Advantageously, the use according to the invention, particularly by topical application, is to increase and / or maintain, advantageously increase, the amount of collagen, particularly type I collagen, preferably collagen fibers, more preferably type I collagen fibers, by increasing and / or maintaining, advantageously by increasing, collagen synthesis and by inhibiting its degradation, particularly of type I collagen, preferentially from collagen fibers, more preferably from type I collagen fibers.

[0028] Another alternative object of the invention relates to the non-therapeutic cosmetic use, advantageously by topical route, of an extract of Lysimachia christinae to further maintain and / or improve the radiance of the complexion of healthy skin and / or healthy mucous membranes, preferably by increasing and / or maintaining the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

[0029] Another alternative object of the invention relates to the non-therapeutic cosmetic use, advantageously by topical application, of an extract of Lysimachia christinae to maintain and / or increase the vitality of healthy skin and / or mucous membranes, preferably by increasing and / or maintaining the synthesis of NAD+ and / or ATP synthesis and / or mitochondrial activity of healthy skin and / or mucous membranes. Thus, advantageously, the use is to maintain and / or increase the synthesis of NAD+ and / or ATP synthesis and / or mitochondrial activity of healthy skin and / or mucous membranes.

[0030] For the purposes of this invention, "cosmetic use" means a non-therapeutic use, that is to say a non-pharmaceutical or non-dermatological use, in other words a use which is not intended for therapeutic use or for the prevention and / or treatment of skin and / or mucous membranes qualified as pathological by a specialist in the field, such as a dermatologist, but is intended for and / or applied to an area of ​​skin and / or mucous membrane(s) said to be healthy.

[0031] For the purposes of the present invention, "topical route" means the direct local application and / or vaporization of the extract according to the invention or of a composition comprising it according to the invention on the surface of the area of ​​skin and / or mucous membranes to be treated.

[0032] For the purposes of this invention, "skin" means any part of the body and / or face, including the scalp. The term "skin" includes It is beneficial for normal, oily, and combination skin. The skin can be Caucasian, African, and / or Asian.

[0033] For the purposes of the present invention, "mucous membrane" means the nasal and / or ocular and / or oral and / or gingival and / or labial and / or vaginal and / or anal and / or urogenital mucous membrane, advantageously the ocular and / or oral and / or labial and / or nasal mucous membranes, more advantageously the labial mucous membrane.

[0034] For the purposes of this invention, "skin and / or mucous membranes" are healthy, meaning that the skin or mucous membrane is considered "non-pathological" by a dermatologist, that is, it does not require therapeutic treatment, in other words, it does not present any infection, scarring (particularly keloid scarring), inflammation such as sunburn, xerosis, wounds, injuries, boils, or any skin disease or condition such as candidiasis, impetigo, psoriasis, eczema, acne, or dermatitis (particularly atopic dermatitis), and / or other dermatoses, rosacea, telangiectasia, solar elastosis, and / or cutis laxa. For the purposes of this invention, healthy skin or healthy mucous membranes are not atopic.In particular, healthy skin or healthy mucous membranes according to the invention are not susceptible to developing acne and / or psoriasis and / or eczema and / or xerosis and / or dermatitis, in particular atopic dermatitis and / or keratosis and / or ichthyosis and / or cheilitis and / or couperose and / or telangiectasias, and / or keloid scars and / or cutis laxa pathology and / or impetigo.

[0035] Advantageously, the skin and / or mucous membrane according to the invention is not dry skin and / or mucous membrane and / or skin and / or mucous membrane with an impaired and / or weakened barrier function. In particular, it is not sensitive and / or atopic and / or reactive and / or sensitized skin and / or mucous membrane.

[0036] Within the scope of the present invention, the extract according to the invention is useful for maintaining and / or improving the biomechanical properties of the skin and / or mucous membranes and / or preventing the decline of these properties. Its use according to the invention is therefore not for moisturizing the skin and / or mucous membranes, and / or protecting the skin and / or mucous membrane barrier, and / or as an antioxidant.

[0037] For the purposes of this invention, "biomechanical properties of healthy skin and / or mucous membranes" means compressive strength, tensile strength, extensibility, and / or resistance to deformation of healthy skin and / or mucous membranes. Preferably, this refers to the firmness and / or tone of healthy skin and / or mucous membranes, the density and / or thickness of the dermis, and / or the vitality of healthy skin and / or mucous membranes, and even more preferably, the firmness of healthy skin and / or mucous membranes.

[0038] For the purposes of this invention, "firmness of healthy skin and / or mucous membranes" means the ability of healthy skin and / or mucous membranes to resist deformation. Firmness can, for example, be measured using conventional techniques known to those skilled in the art. For instance, firmness can be measured in vivo using devices such as an indentometer and a cutometer. The indentometer measures the depth of skin deformation using a ball; the shallower the depth, the firmer the skin. Preferably, firmness is measured according to the protocol in Example 4, and more specifically according to Example 4b.

[0039] The term "improving the firmness of healthy skin and / or mucous membranes" means a significant increase in the firmness value measured after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract, particularly under the conditions of Example 4b. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05.

[0040] "Maintaining the firmness of healthy skin and / or healthy mucous membranes" means preventing and / or preventing the decrease in the firmness of healthy skin and / or healthy mucous membranes, particularly under the effect of aggressive agent(s).

[0041] For the purposes of this invention, "tonicity of healthy skin and / or mucous membranes" means the tone of the skin and / or mucous membranes after a series of deformations, and corresponds to the inverse of "fatigability" or Fatigue. It indicates the ability of healthy skin and / or mucous membranes to deform and return to their original state after a series of deformations, typically after 10 or more. On a graph representing the amplitude of measured deformations on the y-axis and time on the x-axis, tonicity is the area within the curves that encompass the succession of deformations and returns after deformation, designated F3 as described in the DOBREV publication (Application of Cutometer area parameters for the study of human skin fatigue, Skin Research and Technology, 2005, 11: 120-122). This area is therefore the logarithmic mean of the maximum and minimum amplitudes. Tonicity is thus not the same as elasticity, which represents the ability of healthy skin and / or mucous membranes to return to their original state after a single deformation. The more tonic healthy skin or mucous membranes are, the less they fatigue over time.Finally, the larger the area of ​​the logarithmic mean of the maximum and minimum amplitudes, the more toned and less fatigued the healthy skin is. Skin tone can be measured, for example, in vivo using a Cutometer®. This device measures the mechanical properties of the skin by recording its deformation through suction and its return to its original state. Specifically, the tonicity of healthy skin can be measured by performing a series of deformations, typically 10 or more, and recording the area of ​​the deformations and their successive returns—that is, the area defined as the logarithmic mean between the maximum and minimum deformation values. Thus, the larger the deformation area, the greater the skin tone. Preferably, skin tone is measured according to the protocol in Example 4, particularly Example 4a.

[0042] "Improving the tone of healthy skin and / or mucous membranes" means a significant increase in the measured tone value after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract, particularly under the conditions of Example 4a. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05.

[0043] "Maintaining the tone of healthy skin and / or healthy mucous membranes" means preventing and / or preventing the decrease in the tone of healthy skin and / or healthy mucous membranes, particularly after successive deformations, especially under the effect of aggressive agent(s).

[0044] For the purposes of the present invention, "density (of the dermis) of healthy skin and / or healthy mucous membranes" means the protein content of the extracellular matrix synthesized by fibroblasts, in particular collagen fibers, and even more preferably type I collagen fibers. Density can be measured, for example, in vivo and ex vivo (biopsy) using conventional methods, in particular by ultrasound.

[0045] The term "improving the density (of the dermis) of healthy skin and / or mucous membranes" means a significant increase in the density value measured after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05.

[0046] "Maintaining the density (of the dermis) of healthy skin and / or healthy mucous membranes" means preventing and / or stopping the significant decrease in density value in the dermis, particularly collagen fibers, even more preferentially type I collagen fibers, of healthy skin and / or healthy mucous membranes, particularly under the effect of aggressive agent(s).

[0047] For the purposes of this invention, "dermal thickness of healthy skin and / or mucous membranes" means the total height of the dermal layer of healthy skin and / or mucous membranes. Dermal thickness can, for example, be measured in vivo using ultrasound.

[0048] The term "improving the thickness of the dermis of healthy skin and / or mucous membranes" refers to a significant increase in the total dermal height measured after treatment of healthy skin and / or mucous membranes with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract. The significance can be assessed by appropriate statistical tests (Student's t-test) with a significance threshold of p<0.05.

[0049] "Maintaining the thickness of the dermis of healthy skin and / or healthy mucous membranes" means preventing and / or stopping the decrease in the total height of the dermis of healthy skin and / or healthy mucous membranes, particularly under the effect of aggressive agent(s).

[0050] For the purposes of this invention, "inhibiting collagen degradation" means decreasing or preventing the increase in the amount of matrix metalloproteinase(s), particularly type I (MMPI) and / or type III (MMP3) matrix metalloproteinase(s), notably by decreasing and / or preventing the increase in their synthesis and / or secretion in the dermis, particularly under the influence of aggressive agent(s). Collagen degradation can be measured using conventional techniques known to those skilled in the art, in particular according to the protocol described in Examples 3a) and 3b).

[0051] For the purposes of this invention, "radiance of healthy skin and / or mucous membranes" refers to the ability of healthy skin and / or mucous membranes to reflect light, and in particular to the radiance and / or luminosity of healthy skin and / or mucous membranes. The luminosity of healthy skin and / or mucous membranes can be measured in vivo using a Chromameter and corresponds to the value L. The measurement of the radiance of healthy skin and / or mucous membranes can, for example, be carried out in vivo using a Glossimeter®. This device projects light onto the healthy skin or mucous membranes and measures its reflection at a precise angle. The greater the reflection, the more radiant the healthy skin. Preferably, radiance is measured according to the protocol in Example 4, particularly Example 4c.

[0052] Advantageously, "improving the radiance of the complexion of healthy skin and / or healthy mucous membranes" means a significant increase in the radiance value and / or an increase in brightness, measured after treatment of healthy skin and / or healthy mucous membranes with the extract according to the invention, compared to healthy skin and / or healthy mucous membranes not treated with this extract. Radiance is specifically measured under the conditions of example 4c. Significance can be assessed using appropriate statistical tests (Student's t-test) with a significance threshold of p < 0.05. Preferably, skin radiance is measured after 56 days of application, preferably with two applications per day.

[0053] For the purposes of the present invention, "vitality of healthy skin and / or healthy mucous membranes" means the increase and / or maintenance of NAD+ synthesis and / or ATP synthesis and / or mitochondrial activity of healthy skin and / or healthy mucous membranes, preferably the increase and / or maintenance of NAD+ synthesis in fibroblasts of healthy skin and / or healthy mucous membranes.

[0054] Advantageously, the increase in vitality according to the present invention will be a significant increase of at least 30%, preferably at least 50%, and more preferably at least 75%, in NAD+ synthesis in healthy skin and / or mucous membranes treated with the extract according to the invention, compared to healthy skin and / or mucous membranes not treated with this extract. In a particularly advantageous embodiment of the invention, this increase in NAD+ synthesis is measured using techniques well known to those skilled in the art, more preferably under the conditions of Example 5. The significance can be assessed by appropriate statistical tests, such as Student's t-test, with a significance threshold of p < 0.05.

[0055] "Maintaining the radiance of the complexion of healthy skin and / or healthy mucous membranes" means maintaining the radiance and / or luminosity of healthy skin and / or healthy mucous membranes and / or preventing the decrease in radiance and / or luminosity of healthy skin and / or healthy mucous membranes, including under the effect of aggressive agent(s).

[0056] The extract according to the invention is an extract of Lysimachia christinae.

[0057] The extract according to the invention has the advantage of being a cosmetically acceptable active ingredient that does not irritate the skin and has a high It is chemically stable and does not cause allergies. This extract can be produced on an industrial scale.

[0058] Advantageously, the extract according to the invention is topically acceptable. For the purposes of the present invention, "topically acceptable" means an ingredient suitable for topical application, non-toxic, non-irritating to the skin and / or mucous membranes, which does not induce an allergic response and is not chemically unstable.

[0059] The extract according to the invention is obtained from Lysimachia christinae. Advantageously, the Lysimachia christinae extract according to the invention is an extract of aerial parts, even more advantageously of leaves.

[0060] For the purposes of this invention, aerial parts include, in particular, stems, flowers, leaves, fruits, seeds, and mixtures thereof. They do not include roots. Preferably, they refer to stems and leaves, and even more preferably, to leaves.

[0061] Advantageously, the extract according to the invention is therefore not a whole plant extract. Advantageously still, the extract is not a root extract.

[0062] The extract according to the present invention is obtained by any extraction method known to those skilled in the art, chosen from among hot decoction, maceration, extrusion, subcritical extraction, and ultrasonic-assisted extraction, with or without grinding such as ultrasonic grinding or grinding with a mixer. Advantageously, the extract is obtained by maceration and more advantageously by maceration under agitation.

[0063] "Subcritical extraction" means extraction in the presence of water, under conditions of temperature above 100°C and pressure less than or equal to 22.1 MPa (221 bars), such that the water remains in a liquid state but has a viscosity and surface tension lower than that of water at room temperature, increasing its dielectric constant.

[0064] The extraction may be carried out using dry or fresh plant material, advantageously dry, in quantities of 1% to 90% by weight, advantageously 2% to 50%, most advantageously 3% to 25%, preferably 4% to 10%, or preferably 6% to 9%, or even more preferably 7.5%, by weight of plant material relative to the total weight of plant material and extraction solvent.

[0065] The extraction can be carried out at a temperature ranging from 4°C to 300°C, including ambient temperature, i.e. a temperature of about 20°C. In a preferred embodiment of the invention, the extraction will be carried out at a temperature ranging from 20°C to 150°C, preferably from 20°C to 90°C, particularly from 70°C to 90°C, preferably from 75°C to 85°C, more preferably from 80°C.

[0066] The extraction can be conducted for a period of a few seconds to 24 hours, preferably from 1 minute to 12 hours, even more preferably for a period of 5 minutes to 5 hours, more preferably for a period of 0.5 hours to 3 hours, and even more preferably for one hour.

[0067] The extraction can be repeated as many times as necessary with identical or different conditions to the first extraction, preferably the extraction is not repeated.

[0068] Advantageously, the extract according to the invention is obtained by extraction in a solvent or a mixture of protic polar solvent(s), advantageously in water, an alcohol, a glycol, a polyol or a mixture thereof, advantageously also in water as the sole solvent.

[0069] For the purposes of the present invention, "protic polar solvent" means a solvent having a dipole moment and at least one hydrogen capable of participating in hydrogen bonding.

[0070] The extraction solvent may be chosen from water, an alcohol, a glycol, a polyol, a water / alcohol mixture, water / glycol or water / polyol (such as water mixed with ethanol, glycerol and / or butylene glycol and / or other glycols such as xylitol and / or propanediol, etc.) from 99 / 1 to 1 / 99 (w / w), advantageously water as the sole solvent.

[0071] In particular, the extract is obtained by aqueous extraction. For the purposes of the present invention, "extract obtained by aqueous extraction" means any extract obtained by extraction with an aqueous solution containing more than 60% by weight, advantageously at least 70% by weight, in particular at least 80% by weight, more particularly at least 90% by weight, particularly at least 95% by weight, of water relative to the total weight of the aqueous solution, even more advantageously not containing glycol and / or polyol, particularly not containing alcohol, in particular not containing ethanol and / or butanol, more particularly containing only water.

[0072] According to a preferred method, the extract is obtained by maceration in water as the sole solvent, at a temperature above 25°C, in particular 80°C.

[0073] In a preferred method, the extract according to the invention is used alone, in particular as an active ingredient. Said extract according to the invention may be in dry form, that is to say, in powder form, in particular as a freeze-dried powder; advantageously, the extract is freeze-dried.

[0074] According to another preferred embodiment, the extract according to the invention is in the form of an active ingredient in dry form, preferably in powder form, more preferably lyophilized, advantageously in association with maltodextrin, more advantageously the concentration by weight of maltodextrin is between 40% and 95%, preferably between 60% and 90%, more preferably between 75% and 85%, more preferably 80%, relative to the total weight of the active ingredient, in particular the active ingredient comprises the extract and the maltodextrin.

[0075] According to a preferred alternative embodiment, the extract according to the invention may be in liquid form and / or diluted in a solvent, preferably with an extract content of 1% to 99% (w / w), more preferably with an extract content of 5% to 60% (w / w), advantageously with an extract content of 20% to 50% (w / w), and even more advantageously with an extract content of 30% to 50% (w / w) relative to the total weight of the liquid comprising the extract and the solvent. Preferably, this solvent contains less than 20% (w / w) water, even Preferably less than 5% (w / w) water, or even more preferably, the solvent contains no water. Advantageously, this solvent is then of the glycol and / or glycerin type. Very preferably, this solvent is water-soluble.

[0076] According to one embodiment, the extract or composition according to the present invention is administered topically, advantageously on healthy skin and / or healthy mucous membranes. In particular, the use according to the invention is topical use, advantageously on healthy skin and / or healthy mucous membranes.

[0077] According to an advantageous embodiment, the extract or composition according to the invention is administered topically and / or the use according to the invention is topical use on specific parts of the body and / or face, advantageously chosen from the neck, torso, back, abdomen, décolleté, arms, legs, hands, thighs, hips, buttocks, waist, groin, feet, forehead, cheeks, nose, temples, chin, lips and eye contour, the T-zone (forehead, nose and chin), advantageously an area of ​​the face and / or neck, more advantageously chosen from the forehead, cheeks, nose, temples, chin, lips, eye contour and neck.

[0078] Particularly advantageously, the specific part of the body and / or face is an area of ​​healthy tissue exhibiting sagging and / or drooping and / or an area of ​​healthy tissue lacking tone and / or firmness and / or dermal density and / or dermal thickness, and / or an area of ​​healthy skin and / or healthy mucous membrane exhibiting an uneven complexion and / or lacking brightness and / or luminosity and / or radiance and / or vitality.

[0079] In one embodiment of the invention, the extract according to the invention can be used alone, as an active ingredient and / or in a cosmetic composition.

[0080] A "cosmetic ingredient" is defined as one or more plant extracts and / or one or more natural or synthetic molecules and / or mixtures thereof intended for cosmetic use. Cosmetic ingredients are defined in particular by the International Nomenclature of Cosmetic Ingredients (INCI).

[0081] In a particular embodiment of the invention, the extract according to the invention is in the form of a cosmetic composition further comprising a cosmetically acceptable excipient, advantageously a topically acceptable cosmetic excipient.

[0082] For the purposes of this invention, a "cosmetically acceptable" excipient means a compound and / or solvent that is topically acceptable, i.e., an ingredient suitable for topical application, non-toxic, non-irritating, not inducing an allergic response, not chemically unstable, for healthy skin and mucous membranes.The cosmetically acceptable excipient according to the invention can be selected from surfactants, preservatives, buffering agents, swelling agents, chelating agents, biocidal agents, denaturing agents, opacifying agents, pH adjusters, reducing agents, stabilizing agents, emulsifiers, thickeners, gelling agents, film-forming polymers, solvents, fillers, bactericides, odor absorbers, mattifying agents, conditioning agents, texturizing agents, gloss-enhancing agents, pigments, colorants, perfumes and chemical or mineral sunscreens, trace elements, essential oils, sweeteners, taste-modifying agents and a mixture of one or more of these excipients.

[0083] The term "cosmetic composition" means a non-therapeutic composition, that is to say, one which is not intended for therapeutic use or for the prevention and / or treatment of skin and / or mucous membranes classified as pathological by a specialist in the field such as a dermatologist, but which is intended to be and / or applied, advantageously by topical route, to a part of the body said to be healthy, in particular to an area of ​​healthy skin and / or healthy mucous membranes, and which also includes at least one cosmetically acceptable excipient.

[0084] The cosmetic composition or extract according to the invention, possibly in the form of a cosmetic ingredient, may be in all the pharmaceutical forms conventionally used for topical application, such as liquid or solid forms, or even in the form of a liquid or solid under pressure. They may, in particular, be formulated as of a solution, aqueous or oily, an aqueous cream or gel or an oily gel, especially in a jar or tube, especially a shower gel, a shampoo, a milk, an emulsion, a hydrogel, a microemulsion or a nanoemulsion, especially oil-in-water or water-in-oil or multiple or silicone, a serum, a lotion, especially in a glass bottle, a plastic bottle or a dosing bottle or in an aerosol, an ampoule, a liquid soap, a paste, a dermatological bar, an ointment, a mousse, an aerosol, a mask, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of a stick or in powders, especially makeup.In particular the composition is presented in the form of a serum, lotion, cream, milk, ointment, paste, mousse, emulsion, hydrogel, shower gel, aerosol, mask, stick, patch, lacquer, spray, makeup powders or wax, advantageously a cream or lotion.

[0085] In one embodiment of the invention, the composition is administered topically, advantageously on healthy skin and / or healthy mucous membranes.

[0086] In a particular embodiment of the invention, the composition according to the invention is in the form of a serum, lotion, cream, oil, milk, ointment, paste, foam, emulsion, hydrogel, shower gel, aerosol, mask, stick, patch, lacquer, spray, makeup powder or wax.

[0087] In one embodiment of the invention, the extract content of the composition according to the invention is between lxl0 -4 % and 10% (w / w) by weight, preferably between lxl0' 3 % and 10% (w / w) by weight, more preferably between lxl0 -3 % and 3% (w / w) by weight, even more preferably between 0.01% and 3% (w / w) by weight, in particular between 0.01% and 1% (w / w) by weight, of dry matter relative to the total weight of the composition.

[0088] The cosmetic composition according to the invention may also include other ingredients possessing the same properties and inducing a synergistic or non-synergistic effect with the extract according to the invention, or ingredient agents with complementary effects. The extract may be combined with any plant extract. possessing similar properties of maintaining and / or increasing the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0089] The extract can be combined, for example, with cosmetic ingredients to prevent the appearance of pigmentation and / or to enhance skin radiance, including an extract of the mushroom Inonotus obiquus marketed under the name Inolixir™ by the Applicant, an extract of Argania spinosa oil marketed under the name Arganyl™ by the Applicant, an extract of Moringa oleifera seeds marketed under the name Purisoft™ by the Applicant, and / or an extract of lychee marketed under the name Litchiderm™ as antioxidant actives, an extract of chicory marketed under the name Lox-Age™, a yeast extract marketed under the name Vitacell™, an extract of Polygonum bistorta marketed under the name Perlaura™, an extract of galangal marketed under the name Hyalufix™, an extract of corn marketed under the name Deliner™, an extract of Voandzeia subterranea marketed under the name Epigenist™ by the Plaintiff;and / or with cosmetic ingredients to improve skin firmness, in particular by acting on collagen, such as a synthetic tetrapeptide marketed under the name Dermican™, an extract of Hibiscus abeimoschus marketed under the name Linefactor™, a purified pea extract marketed under the name Proteasyl™, an extract of Maniikara muitinervis marketed under the name Elestan™, an extract of Khaya senegaiensis marketed under the name Collalift™ 18, an extract of Argan pulp marketed under the name Argassential™, retinol, vitamin C, an extract of Daviiia rugosa marketed under the name Collguard™, an extract of hydrolyzed soy protein marketed under the name Phytokine™;and / or with cosmetic ingredients active on sensitive skin, including deoiled ungerminated seed protein extract of Moringa oleifera marketed under the trade name Purisoft®, a plant extract of Cestrum iatifo / ium marketed under the name Symbiocell™, a butter extracted from the fruit of the Irvingia gabonensis tree marketed under the name Irwinol™, an extract of Eperua faicata root marketed under the name Eperuline™, a peptide Nacetyl-L-Tyrosyl-L-Prolyl-L-Phenylalaninamide (INCI: Acetyl Tetrapeptide) marketed under the name Skinasensyl™, and / or with; cosmetic ingredients active on the skin and / or mucous microbial flora and / or active on the skin barrier function, including moisturizing and / or soothing agents, among which are an oligosaccharide obtained by enzymatic synthesis marketed by Solabia under the name BioEcolia™ or an alpha-glucooligosaccharide complex marketed by the same company under the name Ecoskin™, an Argania spinosa extract (Lipofructyl™ Argan), a ceramide blend (Sphingoceryl™ VEG), purifying Boldo extracts (Betapur™), inulin- or fructooligosaccharide-based products, bifidobacteria extracts, or an Orthosiphon stamineus extract to combat oily skin (MAT-XS™ Bright), a natural honey extract marketed by the Applicant under the name Melhydran™ for its moisturizing properties, and a flax extract marketed under the name Oligolin™ by the Plaintiff,a biotechnologically modified yeast extract marketed by the Applicant under the name Relipidium™, a Pueraria lobata root extract marketed by the Applicant under the name Inhipase™, a beta-glucan derivative from baker's yeast marketed by Mibelle under the name CM-Glucan Forte™, and / or a Mirabilis jaiapa extract marketed by Sederma under the name Pacifeel™. The extract can be combined, for example, with anti-aging cosmetic ingredients such as a Peucedanum Graveoiens extract marketed by the Applicant under the name Lys'Lastine®V; a Hippophae Rhamnoides extract marketed by the Applicant under the name RNAge™; a Fucus Vesicuiosus extract marketed by the Applicant under the name Seanactiv™; a Nepheiium Lappaceum extract marketed by the Applicant under the names Nephoria® and Nephydrat®; and an extract of Schizandra C / 7 / / 7e / 7s / s marketed by the Applicant under the name Sqisandryl®.

[0090] According to a preferred embodiment, the extract of the invention is not combined with an extract of Gilycyrrhiza giabra and / or an extract of Biettia striata and / or nicotinamide and / or alpha-arbutin. In particular, the extract of the invention is not combined with a mixture of Gilycyrrhiza giabra extract, Biettia striata extract, nicotinamide, and alpha-arbutin.

[0091] In another embodiment of the invention, the cosmetic composition according to the invention does not comprise Gycyrrhiza G. abra extract and / or Blettilla striata extract and / or nicotinamide and / or alpha-arbutin. In particular, the cosmetic composition according to the invention does not comprise a mixture of Gycyrrhiza G. abra extract, Blettilla striata extract, nicotinamide, and alpha-arbutin.

[0092] The cosmetic process

[0093] A second object relates to a non-therapeutic cosmetic treatment process comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae, in particular as described above, or of a cosmetic composition comprising it, in particular as described above, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

[0094] In one embodiment of the invention, the method according to the invention is for maintaining and / or improving the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis, of healthy skin and / or healthy mucous membranes.

[0095] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the firmness of healthy skin and / or healthy mucous membranes.

[0096] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the tone of healthy skin and / or healthy mucous membranes.

[0097] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the density of the dermis of healthy skin and / or healthy mucous membranes.

[0098] In an advantageous embodiment of the invention, the method according to the invention is for maintaining and / or improving the thickness of the dermis of healthy skin and / or healthy mucous membranes.

[0099] In another embodiment of the invention, the method according to the invention for improving and / or maintaining the biomechanical properties of healthy skin and / or healthy mucous membranes, is by increasing and / or maintaining collagen, especially type I collagen, preferentially collagen fibers, more preferentially type I collagen fibers.

[0100] Advantageously, the process according to the invention is for increasing and / or maintaining the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

[0101] Advantageously, the process according to the invention is for maintaining and / or increasing the synthesis of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0102] Advantageously, the process according to the invention is for increasing and / or maintaining collagen synthesis and / or inhibiting collagen degradation, particularly type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

[0103] Advantageously, the process according to the invention is for inhibiting the degradation of collagen, in particular type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers.

[0104] Advantageously, the method according to the invention is to inhibit collagen degradation by decreasing the amount of matrix metalloprotease(s) (MMP), particularly matrix metalloprotease(s) of type I (MMPI) and / or type III (MMP3), preferably said decrease is by decreasing the synthesis and / or secretion of matrix metalloprotease(s) (MMP), particularly of type I (MMPI) and / or type III (MMP3).

[0105] In an alternative embodiment of the invention, the process according to the invention is further to maintain and / or improve the radiance of the complexion of healthy skin and / or healthy mucous membranes, preferably by increasing and / or maintaining the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

[0106] In one embodiment of the invention, the process according to the invention is for maintaining and / or increasing the vitality of healthy skin and / or healthy mucous membranes, advantageously for maintaining and / or increasing the synthesis of NAD+ and / or ATP synthesis and / or mitochondrial activity of healthy skin and / or healthy mucous membranes.

[0107] Another object relates to a non-therapeutic cosmetic treatment process comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae, in particular as described above, or of a cosmetic composition comprising it, in particular as described above, to maintain and / or increase the vitality of healthy skin and / or healthy mucous membranes, advantageously to maintain and / or increase the synthesis of NAD+ and / or ATP synthesis and / or mitochondrial activity of healthy skin and / or healthy mucous membranes.

[0108] In an advantageous embodiment of the invention, the area of ​​healthy skin and / or healthy mucous membranes is an area chosen from an area of ​​the body and / or face, preferably the neck, torso, back, abdomen, décolleté, arms, legs, hands, thighs, hips, buttocks, waist, groin, feet, forehead, cheeks, nose, temples, chin, lips and the eye contour, the T-zone (forehead, nose and chin), advantageously an area of ​​the face and / or neck, more advantageously chosen from the forehead, cheeks, nose, temples, chin, lips, eye contour and neck.

[0109] Particularly advantageously, the area of ​​healthy skin and / or healthy mucous membranes is an area of ​​healthy tissue exhibiting sagging and / or drooping and / or an area of ​​healthy tissue lacking tone and / or firmness and / or density and / or thickness of the dermis and / or an area of ​​healthy skin and / or healthy mucous membranes exhibiting an uneven complexion and / or lacking brightness and / or luminosity and / or radiance and / or vitality.

[0110] In an even more advantageous embodiment, the method according to the invention comprises: - the selection of an area of ​​healthy skin and / or healthy mucous membranes of an individual for which one wishes to improve and / or maintain biomechanical properties of healthy skin and / or healthy mucous membranes, advantageously for which one wishes to maintain and / or improve the firmness and / or tone and / or density of the dermis and / or thickness of the dermis, and / or the vitality of the healthy skin and / or healthy mucous membranes; - the topical application to this area of ​​healthy skin and / or healthy mucous membranes of the extract according to the invention or of a cosmetic composition comprising it, advantageously in an acceptable cosmetic quantity, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes, advantageously to maintain and / or improve the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis, and / or the vitality of healthy skin and / or healthy mucous membranes.

[0111] In an alternative embodiment, the method according to the invention comprises: - the selection of an area of ​​healthy skin and / or healthy mucous membranes of an individual for which one wishes to maintain and / or improve the radiance of the complexion of the healthy skin and / or healthy mucous membranes, advantageously for which one wishes to maintain and / or improve the radiance and / or luminosity of the healthy skin and / or healthy mucous membranes. - the topical application to this area of ​​healthy skin and / or healthy mucous membranes of the extract according to the invention or of a cosmetic composition comprising it, advantageously in an acceptable cosmetic quantity, to maintain and / or improve the radiance of the complexion of healthy skin and / or healthy mucous membranes, advantageously to maintain and / or improve the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

[0112] In one embodiment of the invention, the cosmetic care process according to the invention is characterized in that the extract and / or composition is / are as defined above.

[0113] Preferably, the use according to the invention or the cosmetic process according to the invention comprises the daily topical application of a composition according to the invention, again preferably twice a day for a period of at least 14 days, preferably at least 28 days and even more preferably at least 56 days.

[0114] Other purposes, features and advantages of the invention will become clear to a person skilled in the art upon reading the explanatory description, which refers to examples given only by way of illustration and which shall in no way limit the scope of the invention.

[0115] The examples form an integral part of the present invention, and any feature that appears new compared to any prior art, as described in the entirety including the examples, forms an integral part of the invention in its function and generality. Thus, each example has general application.

[0116] Unless otherwise stated, temperature is expressed in degrees Celsius, ambient temperature is between 20°C and 25°C, and pressure is atmospheric pressure. Percentages are by weight of total volume (w / v).

[0117] Results are expressed as follows: Mean + / - standard deviation. "NA" indicates a result that is not applicable. The significance level was set at 5% (p<0.05) using commonly employed statistical methods known to those skilled in the art, such as Student's t-test or ANOVA. EXAMPLES Example 1: Method for preparing the extract of Lysimachia christinae according to the invention

[0118] Example a) Liquid aqueous extract: The dried aerial parts of the Lysimachia christinae plant were ground and extracted with water (the sole solvent, with a content of 7.5% by weight of dry plant relative to the total weight of plant and solvent) for 1 hour at 80°C. The resulting extract was then filtered and used as is for the various evaluations. The extract is in liquid form.

[0119] Example 1b) Powdered extract: The extract obtained in example a) has been lyophilized. It is in powder form.

[0120] Example 1) Powder composition: Maltodextrin was added to the filtered extract obtained in example 1). The resulting composition was then atomized to produce a powder composed of 80% maltodextrin and 20% Lysimachia christinae extract, by weight relative to the total weight of the composition. The composition is in powder form.

[0121] Example Id) example of a cosmetic formulation according to the invention:

[0122] The ingredients of phases A, B, and C were mixed separately at room temperature. The contents of phase A were added to the contents of phase B, and then the mixture was blended with phase C while stirring. The pH was then adjusted with phase D (citric acid solution) to obtain a pH value between 4.8 and 5. Finally, phase E was added to the mixture and homogenized with an Ultra Turrax®, taking care not to incorporate any air.

[0123] [Table 1] Example 2: Stimulation of type I collagen synthesis

[0124] Normal human dermal fibroblasts obtained from breast biopsies of a 26-year-old donor were cultured in monolayers and grown to confluence in 96-well plates in fibroblast growth medium (Dulbecco's modified Eagle medium (DMEM)) supplemented with 10% fetal bovine serum (F10), glucose, L-glutamine, and antibiotics for 96 hours at 37°C and 5% CO2. The confluent fibroblasts in the defined fibroblast growth medium were treated for 48 hours with or without (untreated control) the product of the invention described in Example 1b). Vitamin C at 50 pM was used as the positive control.

[0125] The culture medium was then removed and an ammonium hydroxide lysis solution was added. The resulting cell lysates were collected for DNA quantification. In parallel, after saturating the matrix with a PBS (Phosphate Buffer Saline) / BSA (Bovine Serum Albumin) solution, incubation was performed with a primary anti-collagen I antibody (commercially available from Novotec) followed by a secondary antibody conjugated to europium (commercially available from Revvity). The fluorescence intensity was read on a Perkin Elmer multi-mode or fluorescence plate reader.

[0126] The results obtained are shown in Table 2 below and are expressed as a percentage of the collagen I deposited relative to the amount of DNA measured in the cells. The untreated control was set at 100%.

[0127] [Table 2]

[0128] The number of replicates is n=6.

[0129] The significance threshold was set at 5% (p<0.05).

[0130] Statistical tests performed: Student's t-test (positive control versus untreated control). Extract from example lb) (lyophilized Lysimachia christinae extract) versus control (One Way ANOVA Holm-Sidack method; significance).

[0131] Co / 7cZvs / d / 7: The product of the invention described in example lb) (formulation according to the invention) induced a significant improvement in type I collagen synthesis by fibroblasts compared to the control. Example 3: Inhibition of the secretion of matrix metalloproteinases I (MMPI) and III (MMP3)

[0132] Example 3a): Inhibition of matrix metalloproteinase I (MMPI) secretion

[0133] Normal human dermal fibroblasts obtained from abdominal biopsies of a 34-year-old donor were cultured in monolayers and grown to confluence in 12-well plates in fibroblast growth medium (fibroblast expansion base medium commercially available from Thermo Fisher Scientific) supplemented with 10% serum of fetal calf (F10), glucose, L-glutamine, and antibiotics were incubated for 96 hours at 37°C and under 5% CO2. Confluent fibroblasts in fibroblast growth medium (Dulbecco's modified Eagle medium (DMEM)) were initially treated with or without (untreated control) the product of the invention described in example lb for 24 hours. Then, the fibroblasts were incubated for 48 hours without any other product (control), with a histone deacetylase (HDAC) inhibitor, sodium butyrate (NaBu), in the presence of Lysimachia christinae extract (Lysimachia christinae conditions in the results table) or without it (NaBu condition in the results).The culture supernatants were then collected, and then 1OOpL of each sample as well as each point of the standard curve were transferred into another microplate in which a human MMP-1 specific antibody (commercially available in kit form from Sigma) was immobilized.

[0134] 1OOpL of MMP-1 standards and samples were placed in the wells and the assembly was incubated for 2.5 h at room temperature; the MMPI present in one sample was bound to the wells by the immobilized antibody.

[0135] The wells were washed using the wash buffer from the kit sold by SIGMA, dried, and 100pL of biotinylated human anti-MMP-1 antibody were added. The plates were then incubated for 1 hour at room temperature. After washing away the unbound biotinylated antibody, 100pL of HRP (horseradish peroxidase) conjugated streptavidin was added to each well, and the plates were incubated at room temperature for 45 minutes. The wells were washed again, and 100pL of an HRP substrate solution was added. Coloration developed proportionally to the amount of bound MMP-1 in each well for 30 minutes. 50pL of the stopping solution (blue to yellow) was added to each well, and the color intensity was measured spectrophotometrically at 450 nm.

[0136] The results obtained are shown in Table 3 below and are expressed as a percentage of the MMP-1 enzyme, with the NaBu condition representing the maximum of 100% protein secretion.

[0137] [Table 3]

[0138] The significance threshold was set at 5% (p<0.05).

[0139] The number of replicates is n=3.

[0140] Statistical test performed: Extract from example lb) versus NaBu (One Way ANOVA Dunnet method). \Ql \ Condusion: The composition according to example lb) (formulation according to the invention) showed a significant inhibition of matrix metalloproteinase type I (MMPI) secretion in a concentration-dependent manner, consequently demonstrating the inhibition of collagen degradation.

[0142] Example 3b): Inhibition of metalloproteinase III (MMP3) secretion

[0143] The same protocol as in example 3a) was used but with the use of a specific human anti-MMP-3 antibody instead of the specific anti-MMP-1 antibody (commercially available in kit form from Sigma).

[0144] The results obtained are shown in Table 4 below and are expressed as a percentage of the MMP-3 enzyme, with the NaBu condition representing the maximum of 100% protein secretion.

[0145] [Table 4]

[0146] The number of replicates is n=3;

[0147] Statistical test performed: Extract from example lb) versus NaBu (One Way ANOVA Holm Sidack method).

[0148] Co / 7cZvs / d / 7: The product of the invention according to example lb) (formulation according to the invention) has shown significant inhibition of matrix metalloproteinase type III (MMP3) secretion in a concentration-dependent manner, consequently demonstrating inhibition of collagen degradation. Example 4: Clinical improvement of skin characteristics after application of the composition of the invention according to example Id)

[0149] The improvements in skin quality resulting from the application of the composition of the invention according to example ld) were evaluated in a clinical trial. The objective of this trial was to assess the effect of the composition of the invention on the biomechanical properties of the skin and / or mucous membranes, in particular skin firmness, tone, and radiance, independently.

[0150] Protocol: The study was designed and conducted as a randomized, double-blind trial in which the efficacy of the invention's composition was compared to the efficacy of a placebo. Two groups of 31 Chinese volunteers aged 33 to 55 years were recruited. One group applied the composition according to Example ld) was formulated at 0.25% (% by weight), and a second group applied a formulation not containing the composition of example ld) (placebo). Both groups applied the formulations to all areas of the face twice a day for 56 days (corresponding to two months). The volunteers' skin is healthy.

[0151] Clinical parameter improvements were assessed using an Indentometer® for skin firmness, a Cutometer® for skin tone, and a Glossimeter® for skin radiance (these devices are marketed by companies such as Courage and Khazaka). Measurements were taken at baseline (D0), and / or after 14 days (D14), and / or after 28 days (D28), and / or after 56 days (D56) of application.

[0152] The results are expressed as percentage improvements in the measured parameters compared to the same parameters measured at the beginning of the study (D0). The improvement provided by the composition according to example ld) is also measured relative to the effects measured with the placebo formulation.

[0153] A statistical analysis of each formulation was performed as follows; all data were analyzed to confirm the normality of the distribution using the Shapiro-Wilk test. The following tests were used to compare the change in clinical parameters after application of the formulation containing the composition according to the invention and the placebo formulation: - For comparisons where the normality of both data sets (product of the invention and placebo) was validated, a paired Student's t-test or an unpaired Student's t-test was used, - if there was no validation of normality, a Wilcoxon Signed-Rank test or a Whitney-Mann Rank test was used.

[0154] Example 4a: Improvement of skin tone (Cutometer®)

[0155] The Cutometer® measures the mechanical properties of the skin by recording the skin's deformation through suction and its return to its original state. Skin tone, or firmness, was measured by performing a succession of deformations (10 minimum) and recording the areas of deformation, where the smaller the amplitude of deformation, the less toned the skin is.

[0156] [Table 5] [7 Conclusion: The composition according to example ld) (formulation according to the invention) showed a significant improvement in skin tone compared to the beginning of the study (DO) at all measurement times (D14, D28 and D56), and a statistically significant improvement superior to that provided by the placebo formulation.

[0158] Example 4b: Improvement of skin firmness (Indentometer®)

[0159] The Indentometer® measures skin firmness by measuring the depth of skin deformation using a ball, where the shallower the depth, the firmer the skin.

[0160] [Table 6] 0161] Conc / us / 'on: The composition according to example ld) (formulation according to the invention) showed a significant improvement in skin firmness compared to the beginning of the study (DO) at D28 and D56, and a statistically significant improvement superior to that provided by the placebo formulation, and this from one month of application (D28).

[0162] Example 4c: Improving skin radiance (Glossimeter®)

[0163] The Glossimeter® allows you to measure the radiance of the skin and / or mucous membranes by projecting a light onto them and measuring the reflection of that light at a very precise angle, where the greater the reflection, the more radiant the skin and / or mucous membrane is.

[0164] [Table 7] _0165] Conc / us / on: The composition according to example ld) (formulation according to the invention) showed a significant improvement in the radiance of the complexion, the luminosity, or the brightness of the skin, compared to the beginning of the study (DO) after 2 months of application (D56). Example 5: Stimulation of NAD+ synthesis

[0166] Normal human dermal fibroblasts were cultured in monolayers in 96-well plates in DMEM (Dulbecco's Modified Eagle Medium) fibroblast growth medium supplemented with 10% fetal bovine serum (F10), glucose, L-glutamine, and antibiotics. for 24 hours at 37°C and under 5% CO2. The fibroblasts were then treated for 24 hours with or without (untreated control) the product of the invention described in Example 1 (Lysimachia christinae extract according to Example 1a) atomized onto maltodextrin at 0.05% (w / v; weight / volume) in the presence of an inhibitor of the NAD+ synthesis enzyme, encoded herein as FK866 hydrochloride hydrate (Sigma) at 1pM. 13-Nicotinamide Mononucleotide (NMN), a precursor of NAD+, was used at 2mM as a positive control, also in the presence of the inhibitor FK866 hydrochloride hydrate at 1pM.

[0167] An NAD+ / NADH assay kit based on a cyclic lactate dehydrogenase reaction is used for NAD+ quantification (MAK460-1KT, Sigma). The reduced form of NAD+, NADH, is reduced to a probe, resulting in a highly fluorescent product.

[0168] The cells are washed with phosphate buffer, pelleted, and homogenized with 100pL of the extraction buffer provided with the kit. The samples are then heated to 60°C, followed by the addition of 20pL of the assay buffer provided with the kit, and then 100pL of another buffer to stop the enzymatic reaction. The mixture is then vortexed and centrifuged at 14,000 x g for 5 minutes. 50pL of the supernatant is transferred to a reading plate, and the fluorescence is read at AEx = 530 nm and AEm = 585 nm on a Thermo Fisher Varioskan™ LUX multimode microplate reader.

[0169] The amount of NAD+ is deduced from a range of NAD+ standards, related to cell viability.

[0170] Cell viability after treatment was verified in parallel with NAD+ measurement using Thiazolyl Blue Tetrazolium Bromide (MTT) reagent. After washing, the cells were incubated with 0.25 mg / mL MTT for 2.5 hours at 37°C. Subsequently, the cells were washed and incubated with 1 mL of Dimethyl Sulfoxide (DMSO). Absorbance was read at 540 nm using a Thermo Fisher Varioskan Flash plate reader.

[0171] The results obtained are shown in Table 8 below and are expressed as a percentage of NAD+.

[0172] [Table 8]

[0173] The number of replicates was n=8 for the product according to the invention and n=12 for the controls. The significance level was set at 5% (p<0.05).

[0174] Statistical test performed: Extract from example (atomized Lysimachia christinae extract) versus control under stress (Student's test). \_QY7 \ Conclusion: The composition according to example le) (extract according to the invention) showed a significant increase in the synthesis of Nicotinamide Adenine Dinucleotide (NAD+) by human dermal fibroblasts, compared to the control under stress (74% increase in NAD+ synthesis), thus demonstrating a significant improvement in skin vitality as well as radiance of complexion.

Claims

Demands

1. Non-therapeutic cosmetic use of an extract of Lysimachia christinae to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

2. Use according to claim 1 to maintain and / or improve the firmness and / or tone and / or density of the dermis and / or thickness of the dermis, of healthy skin and / or healthy mucous membranes, preferably the firmness of healthy skin and / or healthy mucous membranes.

3. Use according to claim 1 or 2 to increase and / or maintain the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

4. Use according to any one of the preceding claims to maintain and / or increase collagen synthesis, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

5. Use according to claim 3 or 4 to inhibit the degradation of collagen, particularly type I collagen, preferably of collagen fibers, more preferably of type I collagen fibers, preferably by decreasing the amount of matrix metalloproteinase(s) (MMP), particularly type I and / or type III matrix metalloproteinase(s).

6. Use according to any of the preceding claims to further maintain and / or improve the radiance of the complexion of healthy skin and / or healthy mucous membranes, advantageously the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

7. Use according to claim 1 to further maintain and / or increase the vitality of healthy skin and / or healthy mucous membranes.

8. Use according to claim 7 to maintain and / or increase NAD+ synthesis and / or ATP synthesis and / or mitochondrial activity of healthy skin and / or healthy mucous membranes.

9. Use according to any one of the preceding claims, characterized in that it is a topical use.

10. Use according to any one of the preceding claims, characterized in that the extract of Lysimachia christinae is an extract of aerial parts, preferably the leaves.

11. Use according to any one of the preceding claims, characterized in that the extract is obtained by extraction in a solvent or mixture of protic polar solvent(s), advantageously in water, an alcohol, a glycol, a polyol or a mixture thereof, advantageously also in water as the sole solvent.

12. Use according to any one of the preceding claims, characterized in that the extract is in the form of an active ingredient in dry form, preferably in powder form, more preferably lyophilized, advantageously in association with maltodextrin, more advantageously the concentration by weight of maltodextrin is between 40% and 95%, preferably between 60% and 90%, more preferably between 75% and 85%, more preferably 80%, relative to the total weight of the active ingredient.

13. Use according to any one of the preceding claims, characterized in that the extract is in the form of a cosmetic composition further comprising a cosmetically acceptable excipient.

14. Use according to claim 13, characterized in that the extract content of the composition is between lxl0 -4 % and 10% (w / w) by weight, preferably between lxl0' 3 % and 10% (w / w) by weight, more preferably between lxl0 -3 % and 3% (w / w) by weight, even more preferably between 0.01% and 3% (w / w) by weight, in particular between 0.01% and 1% (w / w) by weight, relative to the total weight of the composition.

15. Use according to any one of claims 13 or 14, characterized in that the composition is administered topically.

16. Use according to any one of claims 13 to 15, characterized in that the composition is in the form of a serum, lotion, cream, oil, milk, ointment, paste, foam, emulsion, hydrogel, shower gel, aerosol, mask, stick, patch, lacquer, spray, makeup powder or wax.

17. A non-therapeutic cosmetic treatment method comprising the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes of an extract of Lysimachia christinae or a cosmetic composition comprising it, to improve and / or maintain the biomechanical properties of healthy skin and / or healthy mucous membranes.

18. A method according to claim 17, for maintaining and / or improving the firmness and / or tone and / or density of the dermis and / or the thickness of the dermis, of healthy skin and / or healthy mucous membranes.

19. A method according to claim 17 or 18 for increasing and / or maintaining the amount of collagen, in particular type I collagen, preferably collagen fibers, more preferably type I collagen fibers.

20. A method according to any one of claims 17 to 19 for further maintaining and / or improving the radiance of the complexion of healthy skin and / or healthy mucous membranes, advantageously the radiance and / or luminosity of healthy skin and / or healthy mucous membranes.

21. A method according to claim 17 for further maintaining and / or increasing the vitality of healthy skin and / or healthy mucous membranes, advantageously for maintaining and / or increasing the synthesis of NAD+ and / or ATP synthesis and / or mitochondrial activity of healthy skin and / or healthy mucous membranes.

22. A method according to any one of claims 17 to 21, characterized in that the area of ​​healthy skin and / or healthy mucous membranes is selected from a healthy area of ​​the body and / or face preferentially the neck, torso, back, stomach, décolletage, arms, legs, hands, thighs, hips, buttocks, waist, groin, feet, forehead, cheeks, nose, temples, chin, lips and eye contour, the T-zone (forehead, nose and chin), advantageously an area of ​​the face and / or neck, more advantageously chosen from the forehead, cheeks, nose, temples, chin, lips, eye contour and neck.

23. A process according to any one of claims 17 to 22, characterized in that the extract is as defined in any one of claims 10 to 12 and / or the composition is as defined in any one of claims 13 to 16.

Images